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4,4′-Methylene  diphenyl  diisocyanate  (herein  4,4′-MDI)  is  used  in the  production  of
polyurethane  foams,  elastomers,  coatings,  adhesives  and the  like  for a wide  range  of com-
mercial  products.  Occupational  exposure  to  MDI levels  above  current  airborne  exposure
limits can  elicit  immune  mediated  hypersensitivity  reactions  such  as occupational  asthma
in sensitive  individuals.  To  accurately  determine  exposure,  there  has been  increasing  inter-
est in  developing  analytical  methods  to measure  internal  biomarkers  of exposure  to  MDI.
Previous  investigators  have  reported  methodologies  for measuring  MDI diamine  metabo-
lites  and  MDI-Lysine  (4,4′-MDI-Lys)  adducts.  The  purpose  of  this  study  was  to develop
and  validate  an  ultra  performance  liquid  chromatography  isotope  dilution  tandem  mass
spectrometry  (UPLC-ID/MS/MS)  quantitation  method  via  a  signature  peptide  approach  to
enable biomonitoring  of 4,4′-MDI  adducted  to human  serum  albumin  (HSA)  in  plasma.  A
murine,  anti-4,4′-MDI  monoclonal  IgM antibody  was  bound  to magnetic  beads  and  uti-
lized for  enrichment  of  the  MDI adducted  HSA.  Following  enrichment,  trypsin  digestion
was  performed  to generate  the expected  414  site  (primary  site  of  adduction)  4,4′-MDI-
adducted  HSA  signature  peptide  that was  quantiﬁed  by UPLC-ID/MS/MS.  An Agilent  6530
UPLC/quadrupole  time  of  ﬂight  MS (QTOF)  system  was  utilized  for intact  adducted  protein
analysis  and  an  Agilent  6490  UPLC/MS/MS  system  operated  in multiple  reaction  mon-
itoring  (MRM)  mode  was  utilized  for quantiﬁcation  of  the  adducted  signature  peptide
biomarker  both  for  in  chemico  and  worker  serum  samples.  Worker  serum  samples  were
initially  screened  utilizing  the  previously  developed  4,4′-MDI-Lys  amino  acid  method  and
results showed  that  12 samples  were  identiﬁed  as quantiﬁable  for 4,4′-MDI-Lys  adducts.
The  signature  peptide  adduct  approach  was  applied  to the  12  worker  samples  identiﬁed  as
quantiﬁable  for  4,4′-MDI-Lys  adducts.  Results  indicated  no  positive  results  were  obtained
above  the quantiﬁcation  limit  by the signature  peptide  approach.  If the  414  site of lysine
adduction  accounted  for 100%  of  the  4,4′-MDI  adductions  in  the  signature  peptide  adduct
approach,  the  three  highest  quantiﬁable  samples  by  the  4,4′-MDI-Lys  method  should  have
at least  been  detectable  by the  signature  peptide  method.  Results  show  that  although  the
4,4′-MDI  signature  peptide  approach  is more  selective,  it is  18  times  less  sensitive  than
the  4,4′-MDI-Lys  method
4,4′-MDI-Lys  amino  acid  m
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1. Introduction
In commerce, a majority of methylene diphenyl diiso-
cyanate (MDI) is sold as “monomeric MDI” (typically
containing greater than 95% of the 4,4′-MDI isomer)
or “polymeric MDI” (pMDI). These diisocyanates are
important industrial chemicals used in a variety of com-
mercial and consumer applications such as thermoplas-
tic polyurethanes, ﬁbers, sealants, coatings, automotive
bumpers, fenders and fascia, integral-skin plastics, tires and
wheels,  industrial wheels, shoe soles, recreational goods,
and  mechanical goods.
Occupational  exposure to MDI  levels above current
airborne exposure limits can elicit immune mediated
hypersensitivity reactions such as occupational asthma in
sensitive  individuals [1]. Hence, current industrial hygiene
practices such as the utilization of personal protective
equipment are designed to limit exposure below estab-
lished exposure limits obviating potential health effects [1].
An  important tool in the determination of worker expo-
sure  is the measurement of airborne MDI  in the workplace.
However, the external exposure measurements of MDI
may  not be representative of actual internal body burden
levels, thus there has been increasing interest in develop-
ing  analytical methods to measure internal biomarkers of
exposure  for MDI.
An  understanding of the major metabolic pathways for
MDI  provides insight into potential biomarkers to mea-
sure  internal exposure to MDI. Gledhill and coworkers [2]
demonstrated that the major metabolites after inhalation
exposure to 14C-MDI were the mono- and di-acetylated
compounds with the methylene bridge oxidized to various
states.  This supports the most common method, measur-
ing  liberated hydrolysis products following acid digestion
of  protein conjugates in biological ﬂuids. Some researchers
have suggested that methylene diphenyl diamine (MDA)
can  be formed after exposure to MDI, and that the hydrol-
ysis  method could confound biomonitoring efforts for MDI
as  the metabolic products are the same whether there is
MDI  or MDA  exposure [3–11]. Recent work by Wisnewski
and coworkers [12] addresses alternative mechanisms
associated with toluene diamine (TDI) metabolism, which
is  applicable to MDI. This work provides evidence that
accounts for the formation of metabolites observed in the
Gledhill  et al. [2] study without the necessity of invoking
the  presence of free MDA  as an intermediate. Most impor-
tantly, the hydrolysis method while tested [13] has not
been  fully validated, as incomplete release of MDA  from
protein conjugation may  underestimate MDI  exposure lev-
els.
Beyond  hydrolysis measurements, some investigators
have moved to measuring MDI  speciﬁcally adducted to
circulating proteins. Groups have investigated 4,4′-MDI-
hemoglobin adducts at the N-terminal valine [14]. Gries
and  Leng validated a method that measured hydantoin
adducts levels in plasma which formed following acid
treatment of 4,4′-MDI conjugated to the N-terminal amino
acid  [15]. Sufﬁcient sensitivity was achieved to quantify
the  possible adduct levels, however poor analyte recoveries
were  observed following 2 M HCl hydrolysis (2 h at 80 ◦C)
and  solid phase extraction (SPE) cleanup of the biologicalorts 1 (2014) 743–751
samples (or spiked matrix samples). These low recover-
ies  were likely a function of analyte degradation during
the  hydrolysis process or loss of the analyte during the
SPE  cleanup process. Additional work would be required
to  establish if technical modiﬁcations might make this
methodology useful for 4,4′-MDI-hemoglobin adducts, and
if  this methodology would be sensitive enough to inform
worker exposures.
More  recently, Kumar and coworkers have identiﬁed
and quantiﬁed 4,4′-MDI-Lys amino acid adducts in rats
and  humans [16–18]. Both 4,4′-MDI-Lys and acetylated
4,4′-MDI-Lys (AcMDI-Lys) adduct levels were quantiﬁed
from human serum following human serum albumin (HSA)
puriﬁcation, pronase digestion, and SPE cleanup. However,
due  to the lack of a peptide sequence the amino acid adduct
method does not provide HSA protein biomarker conﬁrma-
tion.  As a consequence, the 4,4′-MDI-Lys and AcMDI-Lys
quantitative results rely on the purity of the HSA fraction
collected. Due to the non-speciﬁcity of the albumin puriﬁ-
cation  method utilized, an overestimation in MDI  albumin
adducts levels could result due to adduct contributions
from other proteins.
However,  Wisnewski and coworkers [19] have iden-
tiﬁed 12 MDI  lysine peptide conjugation sites with IgG
on  human albumin which when utilized as a biomarker
of exposure could increase speciﬁcity by not relying on
the  purity of the HSA fraction. Recent advances in the
development of diisocyanate-speciﬁc monoclonal antibod-
ies  have provided a new approach to detecting diisocyanate
adducts [20–22]. The advantages of measuring protein
adduct biomarkers are speciﬁcity for at least one diiso-
cyanate adduct, a slow turnover (i.e., half-life of HSA is
approximately 20 days) and therefore represents a viable
potential tool for monitoring long-term exposure [23,24].
Therefore, to overcome the current selectivity limita-
tions associated with 4,4′-MDI-Lys amino acid biomarker
quantiﬁcation methods described above, we aimed to
develop  and validate a highly speciﬁc HSA signature pep-
tide  approach [25–28] to identify and quantify 4,4′-MDI
HSA  protein adducts formed in chemico and sera from a
human  cohort population. We  employ a highly speciﬁc
IgM  monoclonal antibody to capture the 4,4′-MDI adducted
HSA  proteins from sera, digest the captured adducted
albumin with trypsin to produce the 4,4′-MDI adducted
signature peptide biomarker and analyze with ultra per-
formance liquid chromatography isotope dilution tandem
mass  spectrometry (UPLC-ID/MS/MS).
2.  Methods
2.1. In chemico
2.1.1.  Conjugation of 4,4′-MDI to HSA
To 1 mg/mL  solutions of HSA, 0 mM,  0.01 mM,  0.1 mM
and  1 mM of 4,4′-MDI were added and incubated with rota-
tion  at 37 ◦C for 2 h. Following incubation, each reaction
was  quenched with the addition of 0.5% acetic acid and
vortex-mixed. Excess 4,4′-MDI was  removed by centrifu-
gation (10 min  at 15,000 × g). Samples were transferred
to autosampler vials for intact protein analysis via the
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Table 1
4,4′-MDI HSA derived lysine amino acid and peptide adducts. Underlined
lysine (K) indicates the site of MDI  adduction.
HSA site of adduction MDI  adducted amino
acid  or peptide
MW (g/mol)
Any, non-speciﬁc K 371.11
236 AFKAWAVAR 1242.67
413  YTK 634.22
414 KVPQVSTPTLVEVSR 1862.93
413 KKVPQVSTPTLVEVSR 2255.14
ammonium sulphate precipitation method. The mAb pel-
let  was resuspended in NaHCO3 buffer, dialyzed againstL.G. Luna et al. / Toxico
gilent 6530 UPLC/QTOF (Agilent, Santa Clara, CA) system
s  described below.
.1.2.  HSA-4,4′-MDI adduct stability
To determine stability of the 1 mM 4,4′-MDI adducted
SA, aliquots were stored at room temperature and −80 ◦C.
ach  sample was analyzed on days 1, 4 and 8 after initial
nalysis of freshly prepared adducted HSA by UPLC/QTOF
s described below to determine stability.
.1.3. LC/MS–MS conditions for intact HSA-adduct
nalysis
An Agilent 1290 UPLC system (Agilent, Santa Clara,
A) was utilized for intact adducted protein analysis.
he analytical column utilized was a Zorbax rapid res-
lution 300SB-C18 (part number 863974-302, Agilent)
 × 150 mm-i.d. (3.5 m particle size). The aqueous mobile
hase (A) was 0.1% acetic acid/water, and the organic phase
B)  was 0.1% acetic acid/acetonitrile (ACN). After injection
f  2 L sample onto the column the sample was eluted at
00  L/min from the column using a solvent gradient that
nitially  consisted of 99% A and 1% B for 1 min, and then a
.5%  increase in B for the next 13.5 min  to a ﬁnal concen-
ration of 75% B. The column eluent was introduced into
n  Agilent 6530 QTOF (Agilent) mass spectrometer with an
lectrospray ionization interface. The instrument, operated
n  full scan mode, was utilized for intact adducted protein
nalysis. The instrument was operated in the positive ion
ode  with a survey scan range from 800 to 3000 Da. Instru-
ent  parameters were as follows: gas temperature 350 ◦C,
as  ﬂow 10 L/min, nebulizer 60 psi, fragmentation voltage
as  250 V and the capillary voltage was 3500 V. Instrument
ontrol and data processing were performed with the Mass
unter  software version for B.02.01 data acquisition and
.05.00  for qualitative analysis.
.1.4. HSA adduct digestion
To  determine the extent of adduction, the 1 mM 4,4′-
DI  adducted HSA was digested with trypsin. Speciﬁcally,
 L of the 1 mM 4,4′-MDI adducted HSA and 45 L of
uman plasma (sodium heparin, Bioreclamation, West-
ury,  NY) were transferred to a microfuge tube. Two
undred and ﬁfty L of 50 mM ammonium bicarbon-
te was added to adjust the pH to 7.8. Fifty L of 0.1%
apigest SF (Waters, Milford, MA)  was added to the same
icrofuge tube and incubated for 5 min  at 100 ◦C to solu-
ilize the adducted protein and make it more susceptible
o enzymatic cleavage without inhibiting enzyme activ-
ty.  The sample was allowed to cool to room temperature
nd 20 g (∼45 L) of modiﬁed trypsin (Promega, Madi-
on, WI,  V5113) was added and incubated overnight at
7 ◦C to digest the adducted HSA into predictable trypsin
leaved peptides. The sample was subsequently removed
rom  the incubator and allowed to cool to room tempera-
ure. One hundred L of 175 mM HCl was added to adjust
he  pH to approximately 2 and incubated for an addi-
ional 30 min  at 37 ◦C to break down the Rapigest surfactant
nto small molecules. The sample was removed from the
ncubator and allowed to cool to room temperature. Fifty
ve  L of a 1 g/mL 13C 15N internal standard (ISTD,
VPQVSTPTLV(+6)EVSR) solution was added to the digest.414 KKVPQVSTPTLVEVSR 2255.14
549 KQTALAELVK 1323.66
Final volume was approximately 550 L. The sample was
transferred to an autosampler vial for UPLC-ID/MS/MS
analysis.
The same process described above was followed for
control HSA. Ten mL  of mixed gender unﬁltered human
plasma (sodium heparin, Bioreclamation) aliquoted into
1  mL  increments and stored at −80 ◦C. After the human
plasma was  thawed to room temperature, human plasma
was  digested with trypsin as described above.
2.1.5. MDA adducted amino acid/peptides syntheses
Adduction of lysine with 4,4′-MDI, results in the nucleo-
philic addition of an isocyanate group (N C O)  that
produces a methylene dianaline (MDA) urea adduct on the
lysine  amino acid side chain. To determine the primary site
of  adduction, identiﬁed peptides with a MDA  urea adduct
were  synthesized (New England Peptide, Gardner, MA)  to
lysine  positioned in the 234, 413 and or 414 on various
HSA tryptic peptides to include one missed cleavage at
the  413 and 414 sites of adduction. The unlabeled syn-
thesized MDA  adducted lysine amino acid and peptides
are listed in Table 1 and the peptide adduct synthesis is
shown  in Fig. 1. Fig. 1 illustrates that following hydro-
genation and de-protection during the synthesis process to
produce  an intermediate, MDA  is introduced in excess and
the  ﬁnal cleavage product, the peptide with an MDA  adduct,
is  formed (resulting in a change in molecular weight of
224  Da).
2.1.6.  Monoclonal 4,4′-MDI IgM antibody production
The monoclonal antibody (mAb) 15D-1C4-1C3, an
anti-aromatic and aliphatic diisocyanate IgM producing
hybridoma cell line [20] was  grown in complete DMEM
over a period of three weeks. Culture supernatant was
collected following the splitting of conﬂuent cell lines.
Approximately 2 L of hybridoma culture supernatant was
collected,  centrifuged, and ﬁlter sterilized. Protease activity
was  inhibited by the addition of Roche protease inhibitor
per  500 mL  culture supernatant. The IgM mAb  15D-1C4-
1C3 was  precipitated and concentrated using a saturatedNaHCO3 buffer, and then lyophilized. The lyophilized mAb
was  reconstituted in Dulbecco’s Phosphate-Buffered Saline
(DPBS,  Gibco, Life Technologies, Grand Island, NY) at
1  mg/mL  and stored at −20 ◦C until use.
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2.1.7. Immunoafﬁnity puriﬁcation of MDI  conjugated
proteins
One mL  of secondary coated IgM Dynabeads (110.39D
Invitrogen, Carlsbad, CA) was washed twice with DPBS.
To  the washed secondary coated IgM Dynabeads, 60 L
primary  15D-1C4-1C3 IgM mAb  murine monoclonal anti-
body  was added along with 440 L DPBS and allowed to
incubated with rotation at room temperature for 2 h. After
the  2 h binding period, the supernatant was removed and
antibody-bead complex was washed twice with DPBS and
stored  in 1 mL  DPBS solution at 4 ◦C until needed.
Five L of the 1 mM 4,4′-MDI adducted human albu-
min  was diluted 1:10, 1:100 and 1:1000 in human plasma.
Dilutions were added to 200 L of the above antibody bead
complex and incubated at 37 ◦C with rotation overnight.
After incubation, the supernatant was removed from the
microfuge tubes and the remaining antigen–antibody bead
bound  complex was washed twice with 1 mL  DPBS. The
beads  were resuspended in 50 L of 0.1% Rapigest (Waters,
Milford, MA)  and 250 L of 50 mM ammonium bicarbon-
ate, heated at 100 ◦C for 5 min, allowed to cool to room
temperature, and then 20 g (∼45 L) of sequencing grade
modiﬁed trypsin was added (Promega, V5113). Samples
were brieﬂy vortex-mixed and subsequently incubated onNHO NH2
 the lysine side chain on a peptide.
a  water bath at 37 ◦C overnight. After tryptic digestion,
100 L of 175 mM HCl was  added to adjust the pH to
approximately 2 and an additional incubation at 37 ◦C for
30  min  to break down the acid labile surfactant into small
molecules was  performed. The total ﬁnal digest volume
was  ∼550 L.
2.1.8.  LC/MS–MS conditions for quantiﬁcation of the HSA
adducted peptide biomarker
MDI-peptide  adduct standards were prepared in 50:50
water:acetonitrile with 0.1% formic acid from 1 ng/mL to
200  ng/mL. Matrix standards, with trypsin digested albu-
min  from human serum (A8763, Sigma, St. Louis, MO)  as
the  matrix, were prepared over the same range of con-
centrations. The analytical column utilized was  a 300 SB
RRHD  (Agilent, part number 857750-902) 2.1 × 50-mm-
i.d.  reversed-phase C18 (1.8 m particle size). The aqueous
mobile phase (A) consisted of Milli-Q (18 M) water with
0.1%  formic acid, while the organic phase (B) was ACN
with  0.1% formic acid. The autosampler was programmed
to deliver a 10 L injection. A gradient proﬁle was  utilized
at  a ﬂow rate of 500 L/min. The mobile phase was  held for
1  min  at of 95% A and 5% B and then B was  increased at 19%
L.G. Luna et al. / Toxicology Rep
Table 2
Multiple reaction monitoring transitions and corresponding collision
energies for labeled and unlabeled adducted HSA peptides. Underlined
lysine (K) indicates the site of MDI  adduction.
Adducted peptide Monoisotopic
transition pairs
Optimized
collision
energies
Precursor Product
AFKAWAVAR 622.3 (+2) 673.1 16
KQTALAELVK 662.9 (+2) 844.5 16
YTK 635.3 (+1) 371.2 16
KVPQVSTPTLVEVSR 622.0 (+3) 900.5 18
589.3 18
p
2
a
m
t
i
w
t
m
l
w
g
s
c
t
I
w
a
q
2
2
a
C
h
o
H
c
T
e
t
a
w
a
d
u
5
a
d
a
t
4450.8 18
KVPQVSTPTLVEV(+6)SR 624.3 (+3) 906.5 18
595.3 18
er minute for the next 3.5 min  to a ﬁnal concentration of
8%  A and 72% B, respectively.
An  Agilent 6490 UPLC–MS/MS (Agilent) system oper-
ted in positive ESI multiple reaction monitoring (MRM)
ode  was utilized for quantiﬁcation of the adducted pep-
ide  biomarker. The UPLC column eluent was introduced
nto a 6490 Agilent triple-quadrupole mass spectrometer
ith a jet spray interface. For multiple reaction moni-
oring, the instrument was operated in the positive ion
ode  with mass-to-charge (m/z) MRM  transition pairs
isted  in Table 2. The collision energy for each transition
as optimized. Instrument parameters were as follows:
as  temperature 350 ◦C, gas ﬂow 11 L/min, nebulizer 30 psi,
heath  gas heater 400 ◦C, sheath gas ﬂow 12, and the
apillary voltage was 4000 V. Dwell time was 100 ms  per
ransition and the fragmentation voltage was set to 380 V.
nstrument  control and data processing were performed
ith the Mass Hunter software version for B.04.01 data
cquisition and version B.05.00 for both qualitative and
uantitative analysis.
.2.  In vivo
.2.1. Human sera screened utilizing 4,4′-MDI-Lys amino
cid  methodology
De-identiﬁed sera samples, approved by The Dow
hemical Company human subject review board, from
uman workers with known 4,4′-MDI exposures were
btained from the laboratory of Dr. Jean-Luc Malo at the
ôpital  du Sacré-Coeur de Montréal. Demographic and
lassiﬁcation information for sera samples is provided in
ables  S1–S4. These samples were collected from work-
rs  undergoing speciﬁc inhalation challenge (SIC) in order
o  establish the diagnosis of diisocyanate related asthma
s  part of the worker compensation program. Workers
ere exposed to MDI  in an enclosed-circuit inhalation
pparatus, which maintained a constant concentration of
iisocyanates below 20 ppb. The standardized protocol
sed was exposure of subjects for 1–4 min  on the ﬁrst day,
–30  min  on the second day, and 2 h on the third day, unless
 decrease in FEV1 of 20% or more was observed imme-
iately or 10 min  after stopping exposure. The sensitivity
nd speciﬁcity of 4,4′-MDI HSA adduct determinations via
he  peptide method and to that of the previously published
,4′-MDI-Lys method [17] were compared. Brieﬂy, for theorts 1 (2014) 743–751 747
4,4′-MDI-Lys method, 500 L of human sera albumin (HSA)
was  puriﬁed through a HiTrap Blue column. The puri-
ﬁed  eluent containing the adducted HSA was  subsequently
centrifuged (15 min, 4000 × g) though a 30 kDa molecular
weight cutoff ﬁlter. Two  water washes were performed by
centrifugation of the 30 kDa molecular weight cutoff ﬁl-
ter.  The concentration of the puriﬁed HSA in the retentate
was determined by the bicinchoninic acid assay protein
assay and 10 mg  of puriﬁed albumin/mL was Pronase E
digested  for approximately 12 h at 37 ◦C. Five ng/mL of 13C
15N K ISTD (underlined K indicates MDI  adducted lysine)
was added prior to digestion. After digestion, samples were
cleaned  up utilizing SPE columns (Phenomenex, Strata-X
33u  Polymeric Reversed Phase, 200 mg/3 mL,  part num-
ber  8B-S100-FBJ). The column was  activated with 3 mL  of
methanol  and then equilibrated with distilled de-ionized
water. The sample was applied to the SPE column and
then  washed with 3 mL  of distilled de-ionized water, 3 mL
of  90:10 distilled de-ionized water:methanol and 3 mL of
80:distilled de-ionized water–methanol. The sample was
then  eluted with 6 mL  of 20:80 distilled de-ionized water:
methanol. The SPE eluent was evaporated to dryness and
reconstituted in 100 L of 50 mM  ammonium bicarbon-
ate. Samples were vortex-mixed prior to analysis on an
AB/Sciex 4000 QTRAP.
Supplementary Tables S1–S4 related to this
article can be found, in the online version, at
doi:10.1016/j.toxrep.2014.09.009.
2.2.2. Human sera screened utilizing the 4,4′-MDI
signature peptide adduct methodology
Sera samples that were previously identiﬁed as contain-
ing  4,4′-MDI-Lys adducts [17] were subsequently screened
with  the modiﬁed signature peptide adduct method. To
obtain  deﬁnitive analyses of 4,4′-MDI signature peptide
adducts, a 0.5 mL aliquot of each positive human sera was
allowed  to bind to the primary murine anti-diisocyanate
IgM antibodies, trypsin digested and analyzed as described
previously.
3. Results and discussion
3.1.  In chemico
3.1.1.  Exposure of 4,4′-MDI to HSA
Fig. 2 contains deconvoluted full scan mass spectra
taken in positive ion electrospray ionization mode of (A)
HSA;  (B) 0.01 mM 4,4′-MDI adducted HSA; (C) 0.1 mM
4,4′-MDI adducted HSA; and (D) 1 mM 4,4′-MDI adducted
HSA. Fig. 2A demonstrated two  major isoforms of HSA at
[M+H]+ of 66,440 Da and 66,560 Da consistent with that
previously reported [29–31]. When 0.01 mM of 4,4′-MDI
was  incubated with the HSA (Fig. 2B) adduction appeared
to  be evident and produced a mass difference of 224 indica-
tive  of an MDA  adduction. At the 0.1 mM and the 1 mM
4,4′-MDI concentrations (Fig. 2C and D), MDA  adduction
were apparent on both isoforms, as well as multiple MDI
additions to a single HSA molecule, which may  represent
adduction to multiple amino acid residues and/or polymer-
ization onto a single nucleophilic site. Also evident were the
decreased  signal intensities of both isoforms and increased
748 L.G. Luna et al. / Toxicology Reports 1 (2014) 743–751
spray io
SA. The Fig. 2. Deconvoluted full scan mass spectra taken in positive ion electro
(C)  0.1 mM 4,4′-MDI adducted HSA; and (D) 1.0 mM 4,4′-MDI adducted H
indicates  a second isomer. The change in molecular weight is 224 Da.
signal intensities at m/z ratios at the respective MDA  adduc-
tions.
3.1.2.  HSA adduct stability
MDI-HSA  adducts were analyzed on days 0, 1, 4 and 8
after  preparation. Results demonstrated that the samples
were  stable over the entire 8 days when stored at either
−80 ◦C or room temperature conditions (data not shown).
3.1.3. HSA adduct peptide identiﬁcation
Targeted peptides from the 1 mM 4,4′-MDI adducted
HSA trypsin digest were identiﬁed via data-dependent
UPLC–MS/MS acquisition and subsequent analysis. Results
in  Fig. 3A show the adducted peptide KVPQVSTPTLVEVSR.
A triply charged precursor (M+3H)3+ ion dominant at
a  m/z ratio of 622.0 of the MDI  peptide adduct was
observed. When the precursor ion was subjected to MS/MS
fragmentation, the fragmentation pattern (Fig. 3B) con-
ﬁrmed  the amino acid sequence of the adducted peptide.nization mode of (A) control HSA; (B) 0.01 mM 4,4′-MDI adducted HSA;
single asterisk indicates the ﬁrst isomer of HSA  while the double asterisk
Precursor ions and fragmentation patterns were also
conﬁrmed for K, YTK, KQTALAELVK and AFKAWAVAR
from MDI  adducted HSA. A precursor (M+3H)3+ was
identiﬁed for adducted peptides YTKKVPQVSTPTLVEVSR
and YTKKVPQVSTPTLVEVSR, however ion abundance was
insufﬁcient for MS/MS  fragmentation conﬁrmation.
For conﬁrmation, tandem mass spectrometry analy-
sis  was  performed on the HSA trypsin digests. Full scan
and  fragmentation data ﬁles utilized the Mascot database
search engine (Matrix Science, Boston, MA)  which employs
probability base scoring, signiﬁcance level, mass tolerances
and  sequence query scoring [32] to conﬁrm identiﬁca-
tion of the MDI-derived trypsin digested HSA peptides
from the non-redundant database of the National Center
for  Biotechnology Information (NCBI) for peptide and pro-
tein  adduct identiﬁcation. Results conﬁrmed identiﬁcation
for three 4,4′-MDI HSA trypsin derived peptide adducts:
AFKAWAVAR, KQTALAELVK and KVPQVSTPTLVEVSR (all
peptides have one missed cleavage). The missed cleavage
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Fig. 3. Adducted peptide KVPQVSTPTL
n each peptide is not unexpected due to the large 4,4′-MDI
ubstituent present and likely hindering trypsin’s ability
o  cleave at these sites. The identiﬁed MDI  adducts with
SA  were consistent with those reported by Wisnewski’s
esearch group [19].
.1.4.  Primary site of adduction
For  external calibration purposes, matrix standards
trypsin digested HSA) were prepared from 1 ng/mL to
00  ng/mL. Quantiﬁcation of the 1 mM 4,4′-MDI adducted
SA trypsin digest was performed. No quantiﬁable
mounts resulted for K and YTK. Results showed that
he KVPQVSTPTLVEVSR peptide had a concentration of
76  ng/mL. This resulted in a 10.3% recovery of the
dducted peptide when 0.1 mg  of HSA was digested.
ecovery was 1.2% for the AFKAWAVAR peptide. Thiss-to-Charge (m/z)
(A) full scan and (B) product ion scan.
demonstrates that of the peptides monitored, the pri-
mary  site of adduction appears to be the 414 site,
KVPQVSTPTLVEVSR.
3.1.5. Sensitivity comparison with and without
immunoafﬁnity puriﬁcation
Five  L aliquots of the 1 mM 4,4′-MDI adducted human
albumin (1 mg/mL) were diluted 1:10, 1:100 and 1:1000
in  human plasma. Trypsin digestion was performed on
samples  with and without antibody capture. Results
demonstrated in the absence of immunoafﬁnity puriﬁca-
tion  adducted albumin could only be detected at the 1:10
dilution, while adducted albumin was  non-quantiﬁable at
the  1:1000 dilution. Capture efﬁciency was  99.5%, 70.8%
and  69.4% when the 1 mM 4,4′-MDI adducted human
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Table 3
Summary demographic and classiﬁcation information for all sera samples.
Parameter Exposed to
diisocyanates workers
with  diisocyanate
related asthma n = 15
Exposed to
diisocyanate workers
non-asthmatic no
diisocyante  related
asthma  n = 10
Exposed to
diisocyanates workers
asthmatic  no
diisocyanate related
asthma  n = 9
Not exposed to
diisocyanates
non-asthmatic no
diisocyante  related
asthma  n = 7
Gender
Male 13 8 8 1
Female 2 2 1 6
Age (years) (mean ± SD) 38.5 ± 9.9 36.5 ± 9.9 44.9 ± 7.5 37.9 ± 11.0
Mean (±SD) duration of exposure to
diisocyanates (months)
66.8  ± 83.0 60.5 ± 54.3 152.5 ± 109.3 Not applicable
Last  exposure to diisocyanates prior to
sample collection (mean days ± SD)
94.8 ± 136.9 140.9 ± 113.1 170.9 ± 256.1 Not applicable
Challenge test positive to MDI  Yes No No No
4 detect
1 NQ 
5 ND Detect or non-detect 4 detect 
Sabbioni 4 NQ
Modiﬁed method 7 ND 
albumin was diluted 1:10, 1:100 and 1:1000 in plasma
respectively (n = 1 per protein level).
3.1.6.  Suppression effects with peptide adduct
methodology
Comparison of solvent standards to matrix standards
showed that there is approximately a 30% suppression
effect occurring in the matrix standards. When the internal
standard was added at 100 ng/mL the area counts showed
an  average of 18,040 counts in solvent standards while in
matrix  standards the average internal standard area count
was  12,624 demonstrating a suppression of 30%. A com-
parison of the signal-to-noise ratio was also performed
of the 100 ng/mL matrix standard before and after a 10-
fold  dilution in solvent (50:50 water:acetonitrile with 0.1%
formic  acid). Results demonstrated that the signal-to-noise
ratio of the 100 ng/mL matrix standard prior to dilution
was approximately 114 and after the 10-fold dilution with
solvent  was approximately 29. However, the increased
signal-to-noise ratio achieved by dilution of the matrix
(2.5×) cannot overcome the absolute dilution of the analyte
to  enhance the peptide method detection limit.
3.1.7. Screening of serum samples by the 4,4′-MDI-Lys
amino acid methodology
Human  sera samples from workers with potential
MDI  exposure were puriﬁed for HSA, pronase digestion,
SPE cleaned up and assayed for 4,4′-MDI-Lys as previ-
ously described (Kumar et al. [16]). 4,4′-MDI-Lys could be
detected  in 8 of the 15 MDI-asthmatic workers, but only
4  of the 15 had quantiﬁable levels (Supplementary Table
S1)  and maybe attributable to the half-life of albumin from
when  the date of last exposure took place to the time
the actual sera samples were collected. 4,4′-MDI-Lys was
detectable in a proportion of all workers, independent of
disease  status (Supplementary Tables S1–S4). Overall the
4,4′-MDI-Lys method could quantify adduct levels in 12
human  sera samples from the human cohort above the limit
of  quantiﬁcation (LOQ) for the method (Table 33). Con-
centrations of 4,4′-MDI-Lys ranged from 7.55 to 151 fmol
adducted albumin/mg of albumin with the highest level
of  adduct observed in a non-exposed control. Sabbioni
and coworker’s [17] construction worker cohort identiﬁed 3 detect 1 detect
2 NQ 0 NQ
4 ND 6 ND
15%  of the construction worker controls as positive with
the  4,4′-MDI-Lys method. In the present human cohort,
the  presence of a high level of 4,4′-MDI-Lys observed in
the  non-exposed individual may  be due to either a non-
occupational exposure to MDI  or lack of recognition of use
of  a MDI-containing product.
3.1.8.  Screening of positive serum samples with signature
peptide adduct methodology
The  12 sera positive with quantiﬁable 4,4′-MDI-Lys
adducts were subsequently screened by the 4,4′-MDI-
signature peptide adduct method as described above. No
4,4′-MDI-signature peptide adduct positive results were
obtained from the 12 samples (LOQ = 13.4 fmol adducted
albumin/mg of albumin or matrix LOQ = 134 fmol adducted
albumin/mg of albumin). If the 414 site accounted for 100%
of  the adduction, the three highest quantiﬁable samples
by  the 4,4′-MDI-Lys method should have at least been
detectable by the signature peptide method. However an
additional  5–19 exposure dose dependent lysine adduction
sites  have been demonstrated on HSA [20,22].
4. Conclusions
The MDI  adducted HSA is stable at both −80 ◦C and
room temperature over 8 days. Of the possible HSA peptide
adducts, the 414 adduct (KVPQVSTPTLVEVSR) appears to be
a  primary site of adduction. The peptide adduct method is
18  times less sensitive than the 4,4′-MDI-Lys method thus,
limiting  the ability to detect adduct levels relative to 4,4′-
MDI-Lys  method. While the adducted KVPQVSTPTLVEVSR
peptide method is more selective and potentially the pri-
mary  site of adduction, the additional 5–19 exposure dose
dependent lysine adduction sites have been demonstrated
on HSA, all of which would potentially contribute non-
speciﬁcally to the total 4,4′-MDI-Lys measured following
pronase digestion. Thus, while more speciﬁc, the 4,4′-
MDI-signature peptide method’s sensitivity appears to be
inadequate  for biomonitoring of workers’ exposure to MDI.Biomonitoring is superior to many other exposure
assessment methodologies since it allows assessment of
the  actual exposure on the individual level. While increased
selectivity was  achieved with the signature peptide
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